Histiocytic sarcoma in 14 miniature schnauzers – a new breed predisposition?

Lenz, Jennifer A.; Furrow, Eva; Craig, Linden E.; Cannon, Claire M.

doi:10.1111/jsap.12688

Cited by 27 publications

(29 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…was not confirmed in our study, but the suspected predisposition in Shetland Sheepdogs as proposed previously 13 was confirmed. Miniature Schnauzers have been shown to be predisposed to HS in non-CNS cases, 6 and multiple single cases affecting the CNS have been reported. 14,18,19,34,35 Only 2 Miniature Schnauzers were reported in our series, both with disseminated disease, with no defined breed predisposition based on this limited number of cases.…”

Section: The Previously Reported Predisposition In Labrador Retrieversmentioning

confidence: 99%

“…Several dog breeds are consistently overrepresented in HS case series, and a familial association has been reported in Bernese Mountain Dogs. [3][4][5] Defined breed predisposition data for HS are limited, but Bernese Mountain Dog, Golden Retriever, Flat Coat Retriever, Shar Pei, Miniature Schnauzer, Labrador Retriever, and Pembroke Welsh Corgi breeds have been shown to be overrepresented based on defined control populations, 6,7 and Rottweilers are conspicuously overrepresented in several case series. 1,[8][9][10][11] Histiocytic sarcoma involving the central nervous system (CNS) is relatively uncommon representing 2.2% (n = 2) of primary and 3.4% (n = 7) of secondary intracranial neoplasms diagnosed at necropsy, 12 and prognosis regardless of treatment is anecdotally poor.…”

Section: Introductionmentioning

confidence: 99%

“…-127 vs MST, 5 days; 95% CI, 2-8) and definitively vs palliatively treated disseminated HS (P = .03; MST, 27 days; 95% CI, vs MST, 4 days; 95% CI,[2][3][4][5][6][7][8][9][10][11][12][13][14].…”

mentioning

confidence: 96%

See 2 more Smart Citations

Clinicopathological characteristics of histiocytic sarcoma affecting the central nervous system in dogs

Toyoda

Vernau

Sturges

et al. 2020

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background Histiocytic sarcoma affecting the central nervous system (CNS HS) in dogs may present as primary or disseminated disease, often characterized by inflammation. Prognosis is poor, and imaging differentiation from other CNS tumors can be problematic. Objective To characterize the clinicopathological inflammatory features, breed predisposition, and survival in dogs with CNS HS. Animals One hundred two dogs with HS, 62 dogs with meningioma. Methods Retrospective case series. Records were reviewed for results of cerebrospinal fluid (CSF) analysis, CBC, treatment, and outcome data. Results Predisposition for CNS HS was seen in Bernese Mountain Dogs, Golden Retrievers, Rottweilers, Corgis, and Shetland Sheepdogs (P ≤ .001). Corgis and Shetland Sheepdogs had predominantly primary tumors; Rottweilers had exclusively disseminated tumors. Marked CSF inflammation was characteristic of primary rather than disseminated HS, and neoplastic cells were detected in CSF of 52% of affected dogs. Increased neutrophil to lymphocyte ratios were seen in all groups relative to controls (P <.008) but not among tumor subtypes. Definitive versus palliative treatment resulted in improved survival times (P < .001), but overall prognosis was poor. Conclusions and Clinical Importance Clinicopathological differences between primary and disseminated HS suggest that tumor biological behavior and origin may be different. Corgis and Shetland Sheepdogs are predisposed to primary CNS HS, characterized by inflammatory CSF. High total nucleated cell count and the presence of neoplastic cells support the use of CSF analysis as a valuable diagnostic test. Prognosis for CNS HS is poor, but further evaluation of inflammatory mechanisms may provide novel therapeutic opportunities.

show abstract

Section: The Previously Reported Predisposition In Labrador Retrieversmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinicopathological characteristics of histiocytic sarcoma affecting the central nervous system in dogs

Toyoda

Vernau

Sturges

et al. 2020

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…Treatment varied for the nine dogs, and survival times were poor for those receiving chemotherapy alone, with a median of 19 days. However, one dog who received surgery alone was still alive for 1620 days . Radiographically, PHS is more commonly seen in the right middle and left cranial lung lobes and typically occurs in the periphery rather than the midaspect of the lobe.…”

Section: Introductionmentioning

confidence: 99%

Primary pulmonary histiocytic sarcoma in dogs: A retrospective analysis of 37 cases (2000‐2015)

Marlowe

Robat²,

Clarke

et al. 2018

Vet Comparative Oncology

View full text Add to dashboard Cite

Primary pulmonary histiocytic sarcoma (PHS) has been reported, but is not well characterized. The aim of this retrospective study was to describe clinical characteristics, characterize prognostic factors and report the outcome of a larger group of dogs with primary PHS. Medical records of dogs diagnosed with primary PHS at 11 institutions were retrospectively reviewed. Thirty‐seven dogs were included; 13 received CCNU‐based chemotherapy alone, 18 received surgery and adjuvant CCNU‐based chemotherapy, 3 received medical management alone and 3 dogs received surgery alone. The overall median progression free survival (PFS) and the median survival (overall survival [OS]) were 197 and 237 days, respectively. Measurable responses were noted in dogs receiving only chemotherapy; however, responses were not durable with PFS (91 days) and OS times (131 days) shorter than overall medians. Dogs that received surgery and chemotherapy had significantly prolonged PFS (276 days, P = 0.001) and OS (374 days, P = 0.001), compared with dogs not receiving surgery. As only three dogs undergoing surgery did not receive chemotherapy, it is not possible to determine the contribution of chemotherapy as an adjuvant to surgery. Dogs without evidence of intra‐thoracic metastatic disease were much more likely to undergo surgery (odds ratio = 7.04; P = 0.018). While the presence of metastasis or clinical signs at diagnosis negatively impacted PFS, only the former negatively impacted OS. These data imply that dogs presenting with PHS amenable to surgery (ie, no clinical evidence of metastasis) benefit from surgical intervention; however, the lack of a comparable surgery alone group precludes assessment of the efficacy of post‐surgical adjuvant chemotherapy.

show abstract

“…Recently, a case series of 14 miniature schnauzers described a similar clinical presentation, in which 10 had localised disease and nine of 10 cases were diagnosed with primary pulmonary HS (Lenz et al . ). The median survival time of dogs receiving chemotherapy was only 19 days, although they received varied treatment protocols.…”

Section: Introductionmentioning

confidence: 97%

Histiocytic sarcoma in miniature schnauzers: 30 cases

Purzycka

Peters

Elliott

et al. 2020

J of Small Animal Practice

View full text Add to dashboard Cite

Objectives To summarise the clinical presentation and outcomes in a series of miniature schnauzers diagnosed with histiocytic sarcoma. Materials and Methods Retrospective review of medical records of miniature schnauzers diagnosed with histiocytic sarcoma between 2008 and 2019 at two referral centres in the UK. Signalment, clinical signs at initial presentation, imaging results and clinico‐ and histopathological findings, treatment type and outcome were recorded. Progression‐free survival and overall survival time were calculated. Results Thirty dogs were included. Twenty‐four of 29 dogs undergoing imaging of the thorax had lung and/or mediastinal involvement. The median overall survival time for dogs that were not euthanased within 3 days of diagnosis was 117 days (range 10 to 790). Three dogs underwent surgery; 13 received treatment with lomustine as a sole therapy ‐ with partial responses documented on imaging in five of six dogs and 11 of 13 showing clinical improvement. Clinical Significance Histiocytic sarcoma should be considered as a differential diagnosis for miniature schnauzers with pulmonary masses. Although responses to treatment were common, they were usually short‐lived because of the aggressive nature of the disease.

show abstract

Histiocytic sarcoma in 14 miniature schnauzers – a new breed predisposition?

Cited by 27 publications

References 33 publications

Clinicopathological characteristics of histiocytic sarcoma affecting the central nervous system in dogs

Clinicopathological characteristics of histiocytic sarcoma affecting the central nervous system in dogs

Primary pulmonary histiocytic sarcoma in dogs: A retrospective analysis of 37 cases (2000‐2015)

Histiocytic sarcoma in miniature schnauzers: 30 cases

Contact Info

Product

Resources

About